Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
RADNOR, Pa. — Certara, Inc. (Nasdaq: CERT), a leader in advancing drug development through innovative modeling approaches, is excited to announce the appointment of Adrian McKemey, Ph.D., as President of Drug Development Solutions. Starting immediately, McKemey will oversee the talented global team focused on transforming drug development processes.
Dr. McKemey joins Certara with an impressive background, having held significant leadership positions such as the Head of Enterprise Transformation at IQVIA and Senior Vice President at Quintiles, focused on R&D Strategy Solutions. He brings more than 25 years of dedicated experience driving change in research and development, emphasizing effective business transformation and robust portfolio management. Prior to his roles at IQVIA and Quintiles, he was a Principal at Boston Consulting Group (BCG), where he concentrated on the Life Sciences practice in New York. He completed his Bachelor of Science with First Class honors and received a PhD in High Energy Nuclear Particle Physics from the University of London.
This leadership change falls within Certara's strategic plan, where Patrick Smith, PharmD., will remain pivotal as Senior Vice President of Translational Sciences. Together with his team, Smith has facilitated a cohesive integration of Certara's service offerings, enhancing their capacity to support life sciences clients worldwide.
William Feehery, Ph.D., the CEO of Certara, expressed confidence in McKemey's leadership, stating, “Adrian brings a mission-driven approach to improving drug development. His expertise will enhance our ongoing efforts in biosimulation and scientific services, paving the way for breakthroughs in therapies that change lives.”
Dr. McKemey added, “Certara’s leadership in biosimulation is essential for navigating the complex challenges that have long affected clinical development. The increasing utilization of in silico models in decision-making can significantly elevate the chances of success, both at the asset and portfolio levels. This role, along with the offerings at Certara, affords me a remarkable opportunity to contribute positively to our industry and expedite the delivery of medications to patients.”
Understanding Certara’s Approach to Drug Development
Certara employs advanced biosimulation technology to streamline the traditional drug discovery and development process. The company’s innovative methodologies are utilized globally by over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory bodies across 66 countries.
Through their cutting-edge software and services, Certara helps to identify the best therapeutic candidates and optimize clinical trials, leading to a more efficient development pipeline. The addition of Dr. McKemey is believed to further propel these initiatives, enhancing their capabilities and accelerating time-to-market for new therapies.
Future Directions with New Leadership
With Dr. McKemey at the helm, Certara is poised to deepen its investment in biosimulation and related scientific services. The company recognizes the growing need for innovative solutions that address the complexities of drug development, especially amidst the rapid advancements in personalized medicine and other cutting-edge approaches.
As the landscape of biopharmaceuticals shifts, companies need to leverage data-driven insights to ensure that therapies are effective and address patient needs. Dr. McKemey’s vision aligns with Certara's mission to harness technology to transform drug development and improve outcomes for healthcare systems worldwide.
About Certara
Certara is revolutionizing the drug development landscape by employing biosimulation tools and advanced analytics to shorten the time required to bring safe and effective medications to market. They are committed to providing comprehensive support to their global client base, driving scientific innovation and fostering collaborations that lead to impactful healthcare solutions.
Certara thrives on its collaborative culture and deeply values relationships with clients and partners. This dedication underscores their vision to accelerate innovation in the life sciences sector, ensuring that new treatment solutions reach patients in a timely manner.
Frequently Asked Questions
What role will Dr. Adrian McKemey play at Certara?
Dr. Adrian McKemey will lead the Drug Development Solutions team, focusing on enhancing drug development through biosimulation.
What is the main goal of Certara's drug development approach?
Certara aims to streamline and optimize the drug discovery and development process using advanced biosimulation technologies.
Who was Dr. McKemey's predecessor at Certara?
Patrick Smith, PharmD., will continue at Certara as Senior Vice President of Translational Sciences.
How does Certara support its clients?
Certara provides tools and expertise to over 2,400 biopharmaceutical companies and institutions, helping to improve their drug development strategies.
Where can I learn more about Certara?
More information about Certara and its services can be found on their official website.
